Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211637 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL5775167 | 0.82 | SOD3 (0.33) | — | |
| SCHEMBL368146 | 0.74 | CHRNB2 (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL26645028 | 0.73 | HRH4 (0.38) | PKMHRH4IRAK4ADORA2AHRH3 | |
| Trifluoroacetic Acid SCHEMBL31569309 | 0.71 | IRAK4 (0.36) | PKMHRH4IRAK4HRH3RAD52 | |
| Trifluoroacetic Acid SCHEMBL5767772 | 0.71 | HRH4 (0.38) | PKMHRH4HRH3RAD52UBE2N | |
| Trifluoroacetic Acid SCHEMBL25430229 | 0.69 | NAMPT (0.39) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL31569188 | 0.69 | HRH4 (0.37) | PKMHRH4HRH3RAD52UBE2N | |
| Trifluoroacetic Acid SCHEMBL31569236 | 0.69 | HRH4 (0.37) | PKMHRH4IRAK4HRH3RAD52 | |
| Trifluoroacetic Acid SCHEMBL31569270 | 0.69 | PKM (0.42) | PKMHRH4HRH3RAD52UBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286967-B1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2006-09-27 | — | — | EP | disclosed |
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | PKM 1159/4885HRH4 60/4885IRAK4 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.